专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007042111A3 USE OF ESTRADIOL VALERATE COMBINED WITH DIENOGEST FOR ORAL THERAPY OF DYSFUNCTIONAL UTERINE BLEEDING IN THE FORM OF ORAL CONTRACEPTIVES 审中-公开
标题翻译：戊酸雌二醇联合使用诺孕素子宫出血的DYSF UNKTIONELLEN单元口服避孕药口服治疗
公开(公告)号：WO2007042111A3
公开(公告)日：2007-10-11
申请号：PCT/EP2006008626
申请日：2006-09-05
申请人： SCHERING AG , ZEUN SUSAN , BOUDES POL , ENDRIKAT JAN , SECCI ANGELO , ZIMMERMANN HOLGER
发明人： ZEUN SUSAN , BOUDES POL , ENDRIKAT JAN , SECCI ANGELO , ZIMMERMANN HOLGER
IPC分类号： A61K31/565 , A61K31/57 , A61P15/00 , A61P15/18
CPC分类号： A61K31/565 , A61K31/57
摘要： The invention relates to the use of estradiol valerate combined with 17a- cyanomethyl-17-ß-hydroxyestra-4,9-diene-3on (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. Said combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg, a second phase consisting of 2 groups of daily dose units, whereby the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate and 3 mg dienogest, a third phase consisting of 2 daily dose units having 1 mg estradiol valerate and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. All of the daily dose units of the multi-phase combination and the pharmaceutically harmless placebo correspond to 28 days. The duration of application comprises at least one menstruation cycle and is dependent on individual wishes of the woman with respect to contraception.
摘要翻译：使用戊酸雌二醇与17A-氰甲基-17-SS-hydroxyestra -4,9-二烯-3-酮（地诺孕素），用于产生用于功能性子宫出血在单元出血与口服避孕的口服治疗的多相组合制剂实现相结合。戊酸雌二醇与地诺孕素在这种情况下，组合包含的戊酸雌二醇的2日剂量单元的第一阶段在3毫克，2组的每日剂量单位，的第二阶段，其中，所述第一组2毫克戊酸雌二醇的组合的5日剂量单位和2mg的地诺孕素和第二组17 含有2毫克戊酸雌二醇和3mg地诺孕素，2日剂量单位含有1mg戊酸雌二醇和另一相由药学上可接受的地方 - 博的2日剂量单元的第三阶段的组合的每日剂量单位。多相组合及其药学上无害的安慰剂的整个日剂量单元对应于28天。治疗的持续时间包括至少一个管理周期，并依赖于妇女的个人欲望避孕。

2. 发明申请

WO2005102247A2 MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN 审中-公开
标题翻译：根据天然雌激素避孕更多产品
公开(公告)号：WO2005102247A2
公开(公告)日：2005-11-03
申请号：PCT/EP2005004022
申请日：2005-04-15
申请人： SCHERING AG , ENDRIKAT JAN , DUESTERBERG BERND
发明人： ENDRIKAT JAN , DUESTERBERG BERND
IPC分类号： A61K31/00 , A61K31/56 , A61K31/57 , A61K
CPC分类号： A61K31/57 , A61K31/00 , A61K31/56
摘要： The invention relates to a multi-phase contraceptive preparation that is based on a natural estrogen combined with a synthetic gestagen. Conventional anovulant preparations known in the prior art have proven to be reliable and safe in large-scale application. The aim of the invention is to provide a preparation that offers a higher contraceptive safety over the entire duration of the cycle, improves the cyclic bleeding behavior, and reduces or excludes side-effects, such as tender breasts, headaches, depressive moods, and libido disorders and the like.
摘要翻译：本发明涉及基于天然雌激素与合成孕激素，组合避孕多相产品，其在与已长期被证明是可靠和安全上广泛使用的通用常规排卵抑制制剂，过的整个持续时间比较周期实现更大的避孕可靠性，环状出血行为，并最小化改进的副作用，如乳房触痛，头痛，抑郁情绪和性欲改变等，或排除。

3. 发明申请

WO9723228A3 CONTRACEPTIVE PROCESS AND KIT FOR FEMALE MAMMALS, COMPRISING A COMBINATION OF GESTAGEN AND OESTROGEN 审中-公开
标题翻译：包括GESTAGEN和ESTROGEN组合的女主角的承包过程和工具包
公开(公告)号：WO9723228A3
公开(公告)日：1997-08-28
申请号：PCT/DE9602486
申请日：1996-12-20
申请人： SCHERING AG , ENDRIKAT JAN , DUESTERBERG BERND , REILHAC PIA
发明人： ENDRIKAT JAN , DUESTERBERG BERND , REILHAC PIA
IPC分类号： A61K31/00 , A61K31/565 , A61K31/57 , A61P15/00 , A61P15/18
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： The present invention relates to a female mammal contraceptive process consisting of the sequential administration for at least 28 days of (a) a gestagen in an ovulation-preventing dose for at least 28 days in combination with (b) a natural oestrogen for 5 to 10 days at the end of the sequential dosage of at least 28 days, and a contraception kit.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式